In the context of NSCLC, tumor-derived DCs exhibit overexpression of the T cell co-inhibitory molecule B7-H3, which belongs to the programmed death ligand (PD-L) family, and show reduced stimulation of T cell proliferation compared to controls [485]. This evidence concerns the gene CD276 and neoplasm.